MEI Pharma (MEIP) Stock Price, News & Analysis

Company Overview

MEI Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. The company’s lead programs include pracinostat, an oral histone deacetylase inhibitor being studied in combination with azacitidine for acute myeloid leukemia, ME-401 (umbralisib), a next-generation PI3K-delta inhibitor targeting various B-cell malignancies, and CPI-1205, an EZH2 inhibitor under evaluation in both hematologic and solid tumor indications. MEI Pharma’s pipeline reflects a strategic emphasis on epigenetic and signal-transduction pathways that have the potential to address critical unmet needs in oncology.

Headquartered in San Diego, California, MEI Pharma operates in key clinical research geographies across North America and Europe, collaborating with academic institutions and contract research organizations to advance its clinical trials. The company leverages a combination of in-house discovery capabilities and external partnerships to optimize its development candidates, with a focus on robust study designs and expedited regulatory pathways where warranted. MEI Pharma’s approach aims to move promising compounds efficiently through early- to late-stage trials and ultimately into commercialization.

MEI Pharma was incorporated in the early 2000s and has since evolved into a specialized oncology developer with a seasoned management team. Vamsi N. Mootha, Ph.D., serves as President and Chief Executive Officer, leading a team of industry veterans with backgrounds spanning clinical development, regulatory affairs, and commercial strategy. With a commitment to addressing challenging cancers through targeted therapies, MEI Pharma continues to build on its scientific expertise as it progresses its pipeline toward potential regulatory approval and broader patient access.

Key Stats

• Today's Range: N/A
• 50-Day Range: $2.78 to $5.28
• 52-Week Range: N/A
• Volume: 3.98 million shs
• Average Volume: 1.15 million shs
• Market Capitalization: $104.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MEI Pharma Stock Analysis - MarketRank™

MEI Pharma scored higher than 13% of companies evaluated by MarketBeat, and ranked 899th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for MEI Pharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MEI Pharma are expected to grow in the coming year, from ($5.10) to ($3.71) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MEI Pharma is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MEI Pharma is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.71% of the float of MEI Pharma has been sold short.

Short Interest Ratio / Days to Cover

MEI Pharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MEI Pharma has recently increased by 7.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MEI Pharma does not currently pay a dividend.

Dividend Growth

MEI Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.09

Percentage of Shares Shorted

8.71% of the float of MEI Pharma has been sold short.

Short Interest Ratio / Days to Cover

MEI Pharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MEI Pharma has recently increased by 7.32%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added MEI Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MEI Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.12% of the stock of MEI Pharma is held by insiders.

Percentage Held by Institutions

52.38% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MEIP Stock Analysis - Frequently Asked Questions

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.39) earnings per share for the quarter.

When did MEI Pharma's stock split?

MEI Pharma's stock reverse split on the morning of Monday, April 17th 2023.The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of MEI Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MEI Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), CymaBay Therapeutics (CBAY) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 10/15/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MEIP
• Previous Symbol: NASDAQ:MSHL
• CIK: 1262104
• Web: www.meipharma.com
• Phone: (858) 369-7100
• Fax: 302-655-5049
• Employees: 100
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): ($4.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $17.78 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -77.00%
• Return on Assets: -64.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.78
• Quick Ratio: 16.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: 0.51
• Book Value: $4.96 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 32,838,000
• Free Float: 31,813,000
• Market Cap: $104.72 million
• Optionable: Optionable
• Beta: 0.38